Identification

Name
Propoxyphene napsylate
Accession Number
DB09396
Type
Small Molecule
Groups
Approved
Description

Propoxyphene is a centrally acting narcotic analgesic agent.

Structure
Thumb
Synonyms
  • Dextropropoxyphene napsilate
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Darvon-NTablet, film coated100 mg/1OralStat Rx USA2009-09-25Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Propoxyphene and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)Tablet, film coatedOralAltura Pharmaceuticals, Inc.2010-01-012017-05-09Us
Propoxyphene and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)Tablet, film coatedOralKeltman Pharmaceuticals Inc.2009-03-012017-11-02Us
Propoxyphene Napsylate and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)TabletOralRemedy Repack2011-02-152016-10-13Us
Propoxyphene Napsylate and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)TabletOralAmerincan Health Packaging2009-09-252015-12-29Us
Propoxyphene Napsylate and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)Tablet, film coatedOralRed Pharm Drug, Inc.2009-11-252017-02-14Us
Propoxyphene Napsylate and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)Tablet, film coatedOralLake Erie Medical Dba Quality Care Produts Llc2011-01-252016-12-16Us
Propoxyphene Napsylate and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)Tablet, film coatedOralApotheca, Inc.2009-01-012017-11-04Us
Propoxyphene Napsylate and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)TabletOralRed Pharm Drug, Inc.2009-06-082017-02-11Us
Propoxyphene Napsylate and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)Tablet, film coatedOralRebel Distributors2009-12-012017-11-01Us
Propoxyphene Napsylate and AcetaminophenPropoxyphene napsylate (100 mg/1) + Acetaminophen (650 mg/1)Tablet, film coatedOralbryant ranch prepack2009-11-042016-12-21Us
Categories
UNII
38M219L1OJ
CAS number
Not Available
Weight
Average: 565.73
Monoisotopic: 565.249809154
Chemical Formula
C32H39NO6S
InChI Key
GBKONKCASNNUQD-VGHSCWAPSA-N
InChI
InChI=1S/C22H29NO2.C10H8O3S.H2O/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10;/h6-15,18H,5,16-17H2,1-4H3;1-7H,(H,11,12,13);1H2/t18-,22+;;/m1../s1
IUPAC Name
(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl propanoate naphthalene-2-sulfonic acid hydrate
SMILES
O.OS(=O)(=O)C1=CC2=CC=CC=C2C=C1.CCC(=O)O[[email protected]@](CC1=CC=CC=C1)([[email protected]](C)CN(C)C)C1=CC=CC=C1

Pharmacology

Indication

Propoxyphene is a centrally acting opiate analgesic. It is indicated for the relief of mild to moderate pain

Structured Indications
Pharmacodynamics

Propoxyphene, a synthetic opiate agonist, is structurally similar to methadone. Its general pharmacologic properties are those of the opiates as a group. It binds to the opiate receptors and leads to a decrease of the perception of pain stimuli. Propoxyphene possesses little to no antitussive activity and no antipyretic action. Norpropoxyphene (NP) is a major metabolite of propoxyphene (P), a relatively weak mu-opioid receptor agonist. Toxic blood concentrations ranging from 3 to 180 miromol/L have been reported and the accumulation of NP in cardiac tissue leads to naloxone-insensitive cardiotoxicity.

Mechanism of action

Propoxyphene acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Propoxyphene primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as propoxyphene also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
AKappa-type opioid receptor
agonist
Human
ADelta-type opioid receptor
agonist
Human
Absorption

Peak plasma concentrations of propoxyphene are reached in 2 to 2.5 h. After a 65-mg oral dose of propoxyphene hydrochloride, peak plasma levels of 0.05 to 0.1 μg/mL for propoxyphene and 0.1 to 0.2 μg/mL for norpropoxyphene (major metabolite) are achieved. Repeated doses of propoxyphene at 6 h intervals lead to increasing plasma concentrations, with a plateau after the ninth dose at 48 h.

Volume of distribution

16 L/kg.

Protein binding

80% bound to proteins

Metabolism

Propoxyphene undergoes extensive first-pass metabolism by intestinal and hepatic enzymes. The major route of metabolism is CYP3A4 mediated N-demethylation to norpropoxyphene, which is excreted by the kidneys. Ring hydroxylation and glucuronide formation are minor metabolic pathways.

Route of elimination

In 48 h, approximately 20 to 25% of the administered dose of propoxyphene is excreted via the urine

Half life

6 to 12 hours

Clearance

The renal clearance rate of propoxyphene is 2.6 L/min.

Toxicity

Risk of overdose may include respiratory depression and hypotension

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AmiodaroneThe metabolism of Propoxyphene napsylate can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Propoxyphene napsylate.Approved, Investigational
AprepitantThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Propoxyphene napsylate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Propoxyphene napsylate can be decreased when combined with Atomoxetine.Approved
BoceprevirThe metabolism of Propoxyphene napsylate can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Propoxyphene napsylate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with Bosentan.Approved, Investigational
CarbamazepineThe metabolism of Propoxyphene napsylate can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Ceritinib.Approved
ClarithromycinThe metabolism of Propoxyphene napsylate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Propoxyphene napsylate can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Propoxyphene napsylate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Propoxyphene napsylate can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Propoxyphene napsylate can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Propoxyphene napsylate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Propoxyphene napsylate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Propoxyphene napsylate can be decreased when combined with Delavirdine.Approved
DihydroergotamineThe metabolism of Propoxyphene napsylate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Propoxyphene napsylate can be decreased when combined with Diltiazem.Approved
DoxycyclineThe metabolism of Propoxyphene napsylate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Propoxyphene napsylate can be decreased when combined with Dronedarone.Approved
EnzalutamideThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Propoxyphene napsylate can be decreased when combined with Erythromycin.Approved, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propoxyphene napsylate.Approved
FluconazoleThe metabolism of Propoxyphene napsylate can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Propoxyphene napsylate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Propoxyphene napsylate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Propoxyphene napsylate can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Fusidic Acid.Approved
IdelalisibThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Propoxyphene napsylate can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Propoxyphene napsylate can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Propoxyphene napsylate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Propoxyphene napsylate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Propoxyphene napsylate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Propoxyphene napsylate can be decreased when combined with Ketoconazole.Approved, Investigational
LopinavirThe metabolism of Propoxyphene napsylate can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Propoxyphene napsylate can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Propoxyphene napsylate can be increased when combined with Lumacaftor.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Propoxyphene napsylate.Approved, Investigational
MifepristoneThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with Mitotane.Approved
NefazodoneThe metabolism of Propoxyphene napsylate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Propoxyphene napsylate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Propoxyphene napsylate can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Propoxyphene napsylate can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Propoxyphene napsylate can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Propoxyphene napsylate can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Propoxyphene napsylate can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Propoxyphene napsylate can be increased when combined with Phenytoin.Approved, Vet Approved
PosaconazoleThe metabolism of Propoxyphene napsylate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Propoxyphene napsylate can be increased when combined with Primidone.Approved, Vet Approved
RanolazineThe metabolism of Propoxyphene napsylate can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Propoxyphene napsylate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Propoxyphene napsylate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Propoxyphene napsylate can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Propoxyphene napsylate can be decreased when combined with Ritonavir.Approved, Investigational
SaquinavirThe metabolism of Propoxyphene napsylate can be decreased when combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Propoxyphene napsylate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Propoxyphene napsylate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe metabolism of Propoxyphene napsylate can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Propoxyphene napsylate can be decreased when combined with Telithromycin.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propoxyphene napsylate.Approved, Withdrawn
TiclopidineThe metabolism of Propoxyphene napsylate can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with Tocilizumab.Approved
VenlafaxineThe metabolism of Propoxyphene napsylate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Propoxyphene napsylate can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Propoxyphene napsylate can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Propoxyphene napsylate can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

General References
  1. Ulens C, Daenens P, Tytgat J: Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78. [PubMed:10690289]
  2. Tyers MB: A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol. 1980 Jul;69(3):503-12. [PubMed:6249436]
  3. FDA data [Link]
  4. Drug Information [Link]
  5. Drugs.com [Link]
External Links
PubChem Compound
33544
PubChem Substance
347827841
ChemSpider
30946
ChEBI
51179

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4TerminatedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral100 mg/1
TabletOral
Tablet, film coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00419 mg/mLALOGPS
logP4.06ALOGPS
logP4.9ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)9.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity102.88 m3·mol-1ChemAxon
Polarizability38.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
2-naphthalene sulfonates / 2-naphthalene sulfonic acids and derivatives / Phenylbutylamines / Benzyloxycarbonyls / 1-sulfo,2-unsubstituted aromatic compounds / Phenylpropanes / Aralkylamines / Sulfonyls / Organosulfonic acids / Carboxylic acid esters
show 7 more
Substituents
2-naphthalene sulfonate / Naphthalene sulfonic acid or derivatives / 2-naphthalene sulfonic acid or derivatives / Naphthalene sulfonate / Stilbene / Phenylbutylamine / Benzyloxycarbonyl / Naphthalene / Arylsulfonic acid or derivatives / 1-sulfo,2-unsubstituted aromatic compound
show 25 more
Molecular Framework
Not Available
External Descriptors
hydrate (CHEBI:51179)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Ulens C, Daenens P, Tytgat J: Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78. [PubMed:10690289]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Tyers MB: A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol. 1980 Jul;69(3):503-12. [PubMed:6249436]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Neil A: Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):24-9. [PubMed:6151117]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Neil A: Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):24-9. [PubMed:6151117]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on November 30, 2015 12:10 / Updated on November 09, 2017 04:50